Exabis Library
Welcome to the e-CCO Library!
DOP15: Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP15: Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP15: Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naive ulcerative colitis patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP15: Metabolomics coupled with pathway analysis characterize metabolic changes in treatment-naive Ulcerative Colitis patients
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP15: Results of a pragmatic multicentred randomised controlled trial investigating the use of personalised golimumab dosing in Ulcerative Colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis)
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP15: Transmural healing with vedolizumab in patients with active Crohn’s Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP16: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP16: Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP16: Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP16: The ratio of submucosa thickness to the total bowel wall thickness can be a sonographic parameter to estimate endoscopic remission in Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP16: Transmural healing with vedolizumab in patients with active Crohn’s Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
Thursday, 2 July 2020, 12:10 PM by Eloise Lanaud
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD)
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of inflammatory bowel disease (IBD)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM